HC Wainwright Weighs in on Precigen, Inc.’s Q4 2022 Earnings (NASDAQ:PGEN)

Precigen, Inc. (NASDAQ:PGENGet Rating) – Stock analysts at HC Wainwright boosted their Q4 2022 earnings per share estimates for Precigen in a research report issued to clients and investors on Thursday, November 10th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will earn ($0.05) per share for the quarter, up from their previous estimate of ($0.11). HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.07) per share. HC Wainwright also issued estimates for Precigen’s Q1 2023 earnings at ($0.06) EPS, Q2 2023 earnings at ($0.06) EPS, Q3 2023 earnings at ($0.07) EPS, Q4 2023 earnings at ($0.07) EPS, FY2023 earnings at ($0.27) EPS, FY2024 earnings at ($0.65) EPS, FY2025 earnings at ($0.60) EPS and FY2026 earnings at ($0.25) EPS.

Separately, StockNews.com began coverage on shares of Precigen in a research report on Wednesday, October 12th. They set a “sell” rating on the stock.

Precigen Stock Performance

Shares of PGEN stock opened at $1.84 on Monday. The company has a debt-to-equity ratio of 3.57, a current ratio of 5.51 and a quick ratio of 5.50. The firm has a 50-day moving average of $1.80 and a 200-day moving average of $1.93. Precigen has a one year low of $1.12 and a one year high of $4.45. The company has a market cap of $383.00 million, a P/E ratio of 15.33 and a beta of 1.84.

Insider Activity

In related news, CFO Harry Jr. Thomasian bought 24,500 shares of the company’s stock in a transaction on Tuesday, August 23rd. The shares were purchased at an average cost of $2.09 per share, for a total transaction of $51,205.00. Following the completion of the purchase, the chief financial officer now directly owns 56,390 shares in the company, valued at $117,855.10. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 43.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. lifted its holdings in Precigen by 0.6% during the first quarter. BlackRock Inc. now owns 7,225,641 shares of the biotechnology company’s stock valued at $15,246,000 after purchasing an additional 46,196 shares during the last quarter. Iridian Asset Management LLC CT grew its stake in Precigen by 2.1% in the 2nd quarter. Iridian Asset Management LLC CT now owns 3,761,120 shares of the biotechnology company’s stock valued at $5,040,000 after buying an additional 76,725 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Precigen by 25.7% during the 2nd quarter. Renaissance Technologies LLC now owns 1,492,690 shares of the biotechnology company’s stock valued at $2,000,000 after acquiring an additional 305,100 shares during the period. Northern Trust Corp lifted its position in shares of Precigen by 1.9% during the second quarter. Northern Trust Corp now owns 937,402 shares of the biotechnology company’s stock worth $1,257,000 after acquiring an additional 17,127 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its position in shares of Precigen by 107.1% in the first quarter. Goldman Sachs Group Inc. now owns 849,464 shares of the biotechnology company’s stock valued at $1,792,000 after purchasing an additional 439,368 shares in the last quarter. Institutional investors own 65.22% of the company’s stock.

Precigen Company Profile

(Get Rating)

Precigen, Inc discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and L.

Featured Stories

Earnings History and Estimates for Precigen (NASDAQ:PGEN)

Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.